Tuesday, November 24, 2009, 8:47pm EST - Canadian Markets are closed.
To create a watchlist or portfolio of shares, Sign-in or Register

Neurocrine Biosciences Inc. (NBIX)

 At 16:00 EST: 2.17 USD   0.00 (0.00%)  
MORE ON NBIX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Neurocrine Biosciences, Inc. (NasdaqNM:NBIX) Delayed quote dataEdit
After Hours: 2.17 Down 0.00 (0.02%) as of 4:15pm EST on 11/24/09
Last Trade: 2.17 USD
Trade Time: 4:00PM EST
Change: 0.00 (0.00%)
Prev Close: 2.17
Open: 2.20
Bid: 1.28 x 100
Ask: 3.09 x 100
1y Target Est: 4.50
Day's Range: 2.13 - 2.20
52wk Range: 2.00 - 4.25
Volume: 134,093
Avg Vol (3m): 154,088
Market Cap: 85.08M
P/E (ttm): N/A
EPS (ttm): -1.85
Div & Yield: N/A (N/A%)
Neurocrine Biosciences Inc. (NBIX)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add NBIX to Portfolio   Download Data

HEADLINES
• Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
PRNewswire (Tue 12:00pm)
• NEUROCRINE BIOSCIENCES INC Financials
EDGAR Online Financials (Wed, Nov 4)
• NEUROCRINE BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Oct 29)
• Neurocrine Biosciences, Inc. Q3 2009 Earnings Conference Call
at Seeking Alpha (Thu, Oct 29)
• NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
EDGAR Online (Wed, Oct 28)
• Neurocrine Biosciences Reports Third Quarter 2009 Results
PRNewswire (Wed, Oct 28)
• Q3 2009 Neurocrine Biosciences, Inc. Earnings Release - After Market Close
CCBN (Wed, Oct 28)
• Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results CONFERENCE CALL AND WEBCAST THURSDAY, OC
PRNewswire (Fri, Oct 23)
• NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Thu, Oct 1)
• Neurocrine Biosciences Amends Corporate Headquarters Lease REDUCES LEASING OBLIGATION BY $27 MILLION
PRNewswire (Thu, Oct 1)
More Headlines for NBIX...
ANALYST
EPS Est (next year) (Dec-09) : -1.39
EPS Est (in 2 years) (Dec-10) : -0.87
Avg Rec (current)*: 2.7
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices